Across TCGA pan-cancer cohorts, TULP2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TULP2 data layer compared with 21 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TULP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TULP2 expression acts as an unfavorable survival marker.
PDAC and CCRCC are the cancer types where TULP2 mass-spec protein most reproducibly stratifies survival.